Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Capital Expenditures (2016 - 2026)

Dexcom has reported Capital Expenditures over the past 17 years, most recently at $76.6 million for Q1 2026.

  • Quarterly Capital Expenditures fell 11.95% to $76.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $353.1 million through Mar 2026, down 9.21% year-over-year, with the annual reading at $363.5 million for FY2025, 1.31% up from the prior year.
  • Capital Expenditures was $76.6 million for Q1 2026 at Dexcom, down from $101.9 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $124.6 million in Q4 2024 and troughed at $50.4 million in Q3 2023.
  • The 5-year median for Capital Expenditures is $80.5 million (2025), against an average of $82.4 million.
  • Year-over-year, Capital Expenditures crashed 53.42% in 2023 and then soared 137.33% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $63.5 million in 2022, then decreased by 17.32% to $52.5 million in 2023, then soared by 137.33% to $124.6 million in 2024, then fell by 18.22% to $101.9 million in 2025, then decreased by 24.83% to $76.6 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Capital Expenditures are $76.6 million (Q1 2026), $101.9 million (Q4 2025), and $80.5 million (Q3 2025).